Anti-L-DOPA monoclonal antibody (DMAB4563)

Specifications


Host Species
Mouse
Antibody Isotype
IgG1
Species Reactivity
N/A
Immunogen
Synthetic L-DOPA conjugated to protein carrier (Pc)
Conjugate
Unconjugated

Target


Alternative Names
3 4 dihydroxy L phenylalanine; L dihydroxyphenylalanine; Levodopa; BETA-(3,4-DIHYDROXYPHENYL)-L-ALANINE; HYDROXYTYROSINE; H-PHE(3,4-DI-HYDROXY)-OH

Citations


Have you cited DMAB4563 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


SEROTONERGIC SYSTEM MODULATION HOLDS PROMISE FOR L-DOPA-INDUCED DYSKINESIAS IN HEMIPARKINSONIAN RATS: A SYSTEMATIC REVIEW

EXCLI JOURNAL

Authors: Farajdokht, Fereshteh; Sadigh-Eteghad, Saeed; Majdi, Alireza; Pashazadeh, Fariba; Vatandoust, Seyyed Mehdi; Ziaee, Mojtaba; Safari, Fatemeh; Karimi, Pouran; Mahmoudi, Javad

The alleged effects of serotonergic agents in alleviating levodopa-induced dyskinesias (LIDs) in parkinsonian patients are debatable. To this end, we systematically reviewed the serotonergic agents used for the treatment of LIDs in a 6-hydroxydopamine model of Parkinson's disease in rats. We searched MEDLINE via PubMed, Embase, Google Scholar, and Proquest for entries no later than March 2018, and restricted the search to publications on serotonergic agents used for the treatment of LIDs in hemiparkinsonian rats. The initial search yielded 447 citations, of which 49 articles and one conference paper met our inclusion criteria. The results revealed ten different categories of serotonergic agents, including but not limited to 5-HT1A/BR agonists, 5-HT2AR antagonists, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitor (SNRIs), and tricyclic antidepressants (TCAs), all of which improved LIDs without imposing considerable adverse effects. Although there is promising evidence regarding the role of these agents in relieving LIDs in hemiparkinsonian rats, further studies are needed for the enlightenment of hidden aspect of these molecules in terms of mechanisms and outcomes. Given this, improving the quality of the pre-clinical studies and designing appropriate clinical trials will help fill the bench-to-bedside gap.

The preclinical discovery and development of opicapone for the treatment of Parkinson's disease

EXPERT OPINION ON DRUG DISCOVERY

Authors: Ettcheto, Miren; Busquets, Oriol; Sanchez-Lopez, Elena; Cano, Amanda; Manzine, Patricia R.; Verdaguer, Ester; Olloquequi, Jordi; Auladell, Carme; Folch, Jaume; Camins, Antoni

Introduction Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson's disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. Areas covered This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000-2019). Clinical and post-marketing data are also evaluated. Expert opinion OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket